Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

Two years ago, when Johnson & Johnson announced it was spinning off its consumer brands including Tylenol, Band-Aid, Motrin, ...

Band-Aid and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what ...

American consumer health company Kenvue's Board of Directors announced new actions to unlock shareholder value and an interim ...

With activist investor Starboard Value holding a seat on Kenvue’s board of directors, the consumer healthcare company is ...

Kenvue names interim CEO, begins strategic review to simplify operations and considers divesting smaller beauty brands amid ...

Kenvue’s board of directors are considering ‘a broad range of potential alternatives’ and are hunting for a permanent ...

Kenvue chief executive officer, Thibaut Mongon, has stepped down from the role and the company's board amid an ongoing ...

Kenvue stock approaches a Golden Cross, signaling bullish momentum with the stock up 10% over the past month. Legal win over Tylenol gelcaps boosts Kenvue's momentum, as strong brand power fuels ...

Why It Matters: Kenvue’s stock price has remained relatively unchanged this year, in contrast to the S&P 500 index’s 23% increase.The company’s biggest competitors include Haleon, the parent ...

Kenvue has five brands that generate over $1 billion in sales–Johnson’s, Neutrogena, Listerine, Tylenol, and Aveeno—as well as a number of brands that generate over $400 million in sales ...

Kenvue's CEO and board member Thibaut Mongon has stepped down, it said on Monday, in the second big executive change at the ...